Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. It also provides raw material products, including … Read more
Market Cap & Net Worth: Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (SHE:301211) has a market capitalization of $705.18 Million (CN¥5.17 Billion) as of March 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #12898 globally and #3265 in its home market, demonstrating a -0.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s stock price CN¥12.39 by its total outstanding shares 417600000 (417.60 Million).
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Market Cap History: 2021 to 2026
Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s market capitalization history from 2021 to 2026. Data shows change from $1.69 Billion to $705.18 Million (-18.43% CAGR).
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.71x
Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s market cap is 2.71 times its annual revenue
1.00x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
13.22x
Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s market cap is 13.22 times its annual earnings
9.89x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.69 Billion | $540.62 Million | $121.65 Million | 3.12x | 13.86x |
| 2022 | $1.57 Billion | $514.91 Million | $125.79 Million | 3.06x | 12.51x |
| 2023 | $1.20 Billion | $663.03 Million | $176.12 Million | 1.81x | 6.83x |
| 2024 | $1.21 Billion | $445.86 Million | $91.55 Million | 2.71x | 13.22x |
Competitor Companies of 301211 by Market Capitalization
Companies near Hubei Biocause Heilen Pharmaceutical Co. Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Hubei Biocause Heilen Pharmaceutical Co. Ltd. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Historical Marketcap From 2021 to 2026
Between 2021 and today, Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s market cap moved from $1.69 Billion to $ 705.18 Million, with a yearly change of -18.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥705.18 Million | +1.39% |
| 2025 | CN¥695.50 Million | -42.52% |
| 2024 | CN¥1.21 Billion | +0.57% |
| 2023 | CN¥1.20 Billion | -23.55% |
| 2022 | CN¥1.57 Billion | -6.62% |
| 2021 | CN¥1.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Hubei Biocause Heilen Pharmaceutical Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $705.18 Million USD |
| MoneyControl | $705.18 Million USD |
| MarketWatch | $705.18 Million USD |
| marketcap.company | $705.18 Million USD |
| Reuters | $705.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.